Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer

Addition of bevacizumab, by in large, is cost-ineffective. It can become cost-effective with the ICON-7 protocol, in patients at high risk of progression using biosimilar bevacizumab.